Palleon Pharmaceuticals
Palleon Pharmaceuticals is pioneering glyco-immunology drug development to transform cancer and inflammatory disease treatments, with its lead program E-602 currently in Phase 1/2 clinical trials.
Palleon Pharmaceuticals Overview
Palleon Pharmaceuticals is at the forefront of glyco-immunology drug development, aiming to transform treatments for cancer and inflammatory diseases. The company addresses technical challenges in glycobiology to facilitate drug discovery, patient selection, and indication prioritization. Located at 266 Second Avenue, Waltham, MA 02451, Palleon Pharmaceuticals has raised $147 million in capital and was recognized as a 'Fierce Biotech Fierce 15' Company in 2023.
Palleon Pharmaceuticals Services
Palleon Pharmaceuticals specializes in developing glyco-immunology therapies, leveraging proprietary platforms like EAGLE and HYDRA. The EAGLE platform enables the creation of novel biological therapeutics through the genetic fusion of human sialidase with human monoclonal antibodies. The HYDRA platform, on the other hand, utilizes an immunohistochemistry-based translational research technology to quantify immunosuppressive sialoglycan density in cancer patient samples. These services aim to de-risk clinical developments and enhance patient outcomes.
Palleon Pharmaceuticals Products
Palleon's lead product is E-602, a first-in-class glyco-immune checkpoint inhibitor designed to restore antitumor immunity by degrading immunosuppressive sialoglycans on tumors and immune cells. E-602 is currently in a Phase 1/2 clinical trial known as GLIMMER-01 (NCT05259696). Beyond E-602, the company has a rich pipeline of drug candidates advancing toward IND-enabling studies, targeting conditions such as autoimmune diseases through glycan-editing and Siglec-targeting strategies.
Palleon Pharmaceuticals Clinical Trials
Palleon Pharmaceuticals is evaluating its lead program, E-602, in a Phase 1/2 clinical trial called GLIMMER-01, listed on clinicaltrials.gov under the identifier NCT05259696. This trial aims to assess the safety and efficacy of E-602 in oncology. As of now, the company does not offer its investigational therapies to patients on an expanded access basis. Clinical developments focus on de-risking patient outcomes and advancing glyco-immunotherapy.
Palleon Pharmaceuticals Collaborations
In June 2022, Palleon Pharmaceuticals entered into a strategic collaboration with Henlius to co-develop targeted sialidase molecules. This partnership aims to leverage both companies' expertise to advance the development of innovative therapies. Such strategic collaborations are crucial for Palleon to expand its impact in the field of glyco-immunology and drug development.